Table 2.
Demographics of randomized patients
| Tamoxifen only group (B + D group, N = 655) | Ovarian function suppression group (C + E group, N = 634) | P-value | |
|---|---|---|---|
| Age(mean, years) | 39.7 ± 4.1 | 39.6 ± 4.1 | 0.580 |
| Stage | |||
| I | 178 (27.2 %) | 169 (26.7 %) | 0.977 |
| II | 335 (51.1 %) | 332 (52.4 %) | |
| III | 121 (18.5 %) | 113 (17.8 %) | |
| Unidentified | 21 (3.2 %) | 20 (3.2 %) | |
| Lymph node status | |||
| Negative | 279 (42.6 %) | 275 (43.4 %) | 0.927 |
| Positive | 371 (56.6 %) | 355 (56.0 %) | |
| Unidentified | 5 (0.8 %) | 4 (0.6 %) | |
| Histology | |||
| Invasive ductal carcinoma | 573 (87.5 %) | 560 (88.3 %) | 0.917 |
| Invasive lobular carcinoma | 32 (4.9 %) | 26 (4.1 %) | |
| Others | 42 (6.4 %) | 41 (6.5 %) | |
| Unidentified | 8 (1.2 %) | 7 (1.1 %) | |
| Histologic grade | |||
| G1 | 95(14.5 %) | 118 (18.6 %) | 0.229 |
| G2 | 359 (54.8 %) | 323 (50.9 %) | |
| G3 | 160 (24.4 %) | 151 (23.8 %) | |
| Unidentified | 41(6.3 %) | 42 (6.6 %) | |
| Chemotherapy regimen | |||
| Anthracycline + cyclophosphamide | 184 (28.1 %) | 185 (29.2 %) | 0.782 |
| Anthracycline + cyclophosphamide followed by taxane | 324 (49.5 %) | 318 (50.2 %) | |
| Anthracycline + taxane | 30 (4.6 %) | 29 (4.6 %) | |
| 5-fluorouracil + anthracycline + cyclophosphamide | 74 (11.3 %) | 73(11.5 %) | |
| Others | 21 (3.2 %) | 14(2.2 %) | |
| Unidentified | 22 (3.4 %) | 15 (2.4 %) | |
| Operation | |||
| Total mastectomy | 268 (40.9 %) | 248 (39.1 %) | 0.762 |
| Breast conserving surgery | 382 (58.3 %) | 382 (60.3 %) | |
| Unidentified | 5 (0.8 %) | 4 (0.6 %) |